Articles related to MEDICAL UNIVERSITY PRESS

Discover the pioneering research connecting marijuana use with modifications in the human epigenome. The study brings to light potential health implications and illuminates areas for future exploration.

The discovery of lactate’s potential to rejuvenate immune cells and combat cancer opens up exciting new avenues in the field of immunotherapy. Dive in to uncover how a simple metabolic byproduct could drastically reshape cancer treatment strategies.

Gain insight into how a shift in cellular environment and UV radiation exposure can instigate additional mutations, deepening our understanding of the evolution and development of rare and complex malignancies such as BPDCN.

Utilizing an AI-powered smart otoscope, Drs. Clark and Canares have set a new standard for diagnosing ear infections, providing real-time, highly accurate diagnoses that can greatly benefit patient care across various healthcare settings.

Roswell Park Comprehensive Cancer Center Shines at ASCO 2023 Roswell Park Comprehensive Cancer Center recently showcased a series of groundbreaking research studies at the American Society of Clinical Research (ASCO) 2023 meeting, highlighting their commitment to advancing cancer management and clinical trials. “This study has revealed differences in transcriptional metabolic profiles and other drivers of disease, as well as immune profiles, between younger and older CRC populations. This biology should be explored in the future, as new avenues for treatment in younger CRC populations.” Dr. Deepak Vadehra from the “Transcriptional metabolic profiling in young onset colorectal cancer (CRC) patients” study

An experimental drug called 32-134D shows promise in preventing or slowing vision loss in individuals with diabetes, according to a study conducted by researchers at the Wilmer Eye Institute, Johns Hopkins Medicine. The study, which utilized mouse models, human retinal organoids, and eye cell lines, focused on proliferative diabetic retinopathy and diabetic macular edema. The findings, published in the Journal of Clinical Investigation, indicate that 32-134D reduced levels of a protein called HIF, which is responsible for diabetic retinal vascular disease. The drug was found to be safer than another HIF-targeting treatment under investigation. Dr. Akrit Sodhi, the author of the study, emphasizes the drug’s well-tolerated nature and its ability to effectively reduce HIF levels in diseased eyes. Elevated levels of HIF in the eyes lead to increased blood vessel production and leakage in the retina, contributing to vision loss. The researchers tested 32-134D on human retinal cell lines and observed a return to near-normal gene expression levels, halting the creation of new blood vessels and maintaining vascular integrity. The drug was also tested on mouse models, resulting in diminished HIF levels and inhibition of new blood vessel formation and leakage. Remarkably, the drug exhibited active levels in the retina […]